PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW146319View Pathway |
drug action
Tocopherol Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:55 Last Updated: October 07, 2023 at 17:55 |
PW145874View Pathway |
drug action
Tofacitinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:52 Last Updated: October 07, 2023 at 16:52 |
PW176479View Pathway |
Tofacitinib Predicted Metabolism PathwayHomo sapiens
Metabolites of Tofacitinib are predicted with biotransformer.
|
Creator: Omolola Created On: December 12, 2023 at 16:21 Last Updated: December 12, 2023 at 16:21 |
PW127726View Pathway |
drug action
Tolazamide Action PathwayHomo sapiens
Tolazamide is an hypoglycemic agent from the sulfonylurea class used in the treatment of non insulin dependent diabetes mellitus type II. Tolazamide lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. This drug binds to ATP-sensitive potassium-channel receptors on the pancreatic cell surface (known as the sulfonylurea receptor 1 (SUR1) subunit (Kir6.2)), reducing potassium conductance and causing depolarization of the membrane. This depolarization stimulates the calcium ion influx through voltage-sensitive calcium channels thus raising intracellular concentrations of calcium ions. The higher concentration of intracellular calcium ions induces the secretion (exocytosis) of insulin into the blood. Tolazamide is administered as an oral tablet.
|
Creator: Daphnee Created On: May 26, 2023 at 12:05 Last Updated: May 26, 2023 at 12:05 |
PW144944View Pathway |
drug action
Tolazamide Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:46 Last Updated: October 07, 2023 at 14:46 |
PW176149View Pathway |
Tolazamide Predicted Metabolism Pathway newHomo sapiens
Metabolites of Tolazamide are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:20 Last Updated: November 29, 2023 at 14:20 |
PW132365View Pathway |
Tolazoline Drug MetabolismHomo sapiens
Tolazoline is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Tolazoline passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 21:14 Last Updated: September 21, 2023 at 21:14 |
PW144904View Pathway |
drug action
Tolazoline Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:40 Last Updated: October 07, 2023 at 14:40 |
PW127737View Pathway |
drug action
Tolbutamide Action PathwayHomo sapiens
Tolbutamide is an oral antihyperglycemic agent from the sulfonylurea drug class. This drug is used to treat hyperglycemia in patients with type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus (NIDDM)). It is structurally similar to acetohexamide, chlorpropamide, and tolazamide. Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from beta cells of pancreatic islet tissue. Sulfonylureas inhibit the ATP-potassium channels by linking with the subunit called the ATP-binding cassette sub-family C member 8 on the beta cell membrane and potassium efflux. This binding results in the depolarization of the cell. In consequence, it causes an influx of calcium ions thus releasing the insulin-containing granules by exocytosis. This drug is also an inhibitor of the ATP-sensitive inward rectifier potassium channel 1 presents in the kidney. Its pharmacological action is still unknown. Tolbutamide is administered as an oral tablet.
|
Creator: Daphnee Created On: May 29, 2023 at 16:41 Last Updated: May 29, 2023 at 16:41 |
PW145213View Pathway |
drug action
Tolbutamide Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:19 Last Updated: October 07, 2023 at 15:19 |